Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 15723608)

1.
2.
3.

[How about the uncertainty in the haplotypes in the population-based KORA studies?].

Heid IM, Lamina C, Bongardt F, Fischer G, Klopp N, Huth C, Küchenhoff H, Kronenberg F, Wichmann HE, Illig T.

Gesundheitswesen. 2005 Aug;67 Suppl 1:S132-6. German.

PMID:
16032531
4.

Pharmacogenetics in drug regulation: promise, potential and pitfalls.

Shah RR.

Philos Trans R Soc Lond B Biol Sci. 2005 Aug 29;360(1460):1617-38. Review.

5.

Genetic interaction between NAT2, GSTM1, GSTT1, CYP2E1, and environmental factors is associated with adverse reactions to anti-tuberculosis drugs.

Costa GN, Magno LA, Santana CV, Konstantinovas C, Saito ST, Machado M, Di Pietro G, Bastos-Rodrigues L, Miranda DM, De Marco LA, Romano-Silva MA, Rios-Santos F.

Mol Diagn Ther. 2012 Aug 1;16(4):241-50. doi: 10.2165/11634480-000000000-00000.

PMID:
22788240
6.

Expanding role of pharmacogenomics in the management of cardiovascular disorders.

Yip VL, Pirmohamed M.

Am J Cardiovasc Drugs. 2013 Jun;13(3):151-62. doi: 10.1007/s40256-013-0024-5. Review.

PMID:
23579966
7.

Data science approaches to pharmacogenetics.

Penrod NM, Moore JH.

Curr Mol Med. 2014;14(7):805-13. Review.

PMID:
25109795
8.

Pharmacogenetics of osteoporosis: future perspectives.

Marini F, Brandi ML.

Calcif Tissue Int. 2009 May;84(5):337-47. doi: 10.1007/s00223-009-9226-x. Epub 2009 Mar 7. Review.

PMID:
19271099
9.

Health-related disparities: influence of environmental factors.

Olden K, White SL.

Med Clin North Am. 2005 Jul;89(4):721-38. Review.

PMID:
15925646
10.

Human inter-individual DNA sequence variation in candidate genes, drug targets, the importance of haplotypes and pharmacogenomics.

Hoehe MR, Timmermann B, Lehrach H.

Curr Pharm Biotechnol. 2003 Dec;4(6):351-78. Review.

PMID:
14683431
11.

Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.

Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G.

Health Technol Assess. 2001;5(33):1-56. Review.

12.

[Posttraumatic stress disorder (PTSD) as a consequence of the interaction between an individual genetic susceptibility, a traumatogenic event and a social context].

Auxéméry Y.

Encephale. 2012 Oct;38(5):373-80. doi: 10.1016/j.encep.2011.12.003. Epub 2012 Jan 24. Review. French.

PMID:
23062450
13.

Linking pharmacovigilance with pharmacogenetics.

Clark DW, Donnelly E, Coulter DM, Roberts RL, Kennedy MA.

Drug Saf. 2004;27(15):1171-84.

PMID:
15588114
14.

Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity.

Acuña G, Foernzler D, Leong D, Rabbia M, Smit R, Dorflinger E, Gasser R, Hoh J, Ott J, Borroni E, To Z, Thompson A, Li J, Hashimoto L, Lindpaintner K.

Pharmacogenomics J. 2002;2(5):327-34.

15.

Pharmacogenetics of psychotropic drug response.

Malhotra AK, Murphy GM Jr, Kennedy JL.

Am J Psychiatry. 2004 May;161(5):780-96. Review.

PMID:
15121641
17.

[SNP database and establishment of personalized medicine].

Inoue I.

Nihon Yakurigaku Zasshi. 2002 Nov;120(1):41P-42P. Review. Japanese.

PMID:
12491775
18.

Cardiovascular pharmacogenetics in the SNP era.

Mooser V, Waterworth DM, Isenhour T, Middleton L.

J Thromb Haemost. 2003 Jul;1(7):1398-402. Review.

PMID:
12871273
19.
20.

Testing and estimating gene-environment interactions in family-based association studies.

Vansteelandt S, Demeo DL, Lasky-Su J, Smoller JW, Murphy AJ, McQueen M, Schneiter K, Celedon JC, Weiss ST, Silverman EK, Lange C.

Biometrics. 2008 Jun;64(2):458-67. Epub 2007 Oct 25.

PMID:
17970814
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk